Table 1. SHH, GLI1, GLI2, GLI3, and PTCH1 expression in human prostate cancer.

	SHH		PTCH1		GLI1		GLI2		GLI3
Patient	Fold increase	Range	Fold increase	Range	Fold increase	Range	Fold increase	Range	Fold increase	Range
829	0	0-0.01	1.5	1.1-2.1	26.1	20.8-32.7	0.02	0.02-0.02	72	53-99
887	0.2	0.05-0.9	8.5	7.6-9.5	0.09	0.07-0.13	0.43	0.37-0.51	1.1	0.8-1.6
921	2.9	1.3-6.3	50	30-84	2	1.1-3.4	3.8	2.4-6.1	12.5	7.7-20.4
945	9.8	6.2-15.7	7.8	5.7-10.7	22.7	21.6-23.9	0.7	0.5-1.0	2.2	2.1-2.4
1854	4.7	1.8-11.7	213	164-278	5.1	3.8-6.9	19.5	10.9-35.1	5.7	4.4-7.5
1866	4.6	4.1-5.2	3.4	3.1-3.7	299	260-342	0.03	0.02-0.03	0.18	0.15-0.2

Fold increase in gene expression in tumors versus matched normal tissue determined by real-time RT-PCR analyses as calculated by the ΔCT method. Range indicates ± 1 SD. Gene expression levels were normalized to β-actin. Increases of 2-fold or more are shown in bold.